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Materials and Methods: 30 lesions from 23 malignant astrocytomas (2 
AAs and 21 GBMs) were enrolled. Before irradiation, Met-PET was 
performed in all cases. In each ROI, maximum uptake of Met was 
determined relative to a corresponding contralateral region 
(Tmax/Nave). Among the 23 patients, 10 were treated by 3D-CRT with 
conventional fractionation (40Gy/20Fxs for FLAIR-high area with boost 
of 20Gy/10Fxs for enhanced lesion), while the remaining 13 were 
treated by hypofractionated high-dose IMRT. In the IMRT, 3-layered 
PTVs were contoured (PTV-1: enhanced lesion with 5mm margin, PTV-
2: 15mm surrounding the PTV-1,PTV-3: FLAIR-high area) and different 
doses (68Gy for PTV-1, 40Gy for PTV-2 and 32Gy for PTV-3) were 
delivered by 8 fractions. Concurrent and adjuvant temozolomide was 
administrated in all cases. After treatment, MRI was performed with 
an interval of 1 or 2 months. If the recurrent tumor was observed, 
Met-uptake at the recurrent point and delivered dose at the same 
point in the treatment plan of irradiation were retrospectively 
calculated. The delivered dose was standardized using biologically 
effective dose (BED, alpha/beta=10). The ratio of Met-uptake/BED 
was compared with tumor control using logistic regression analysis, 
and optimal threshold was calculated from ROC curves. The patients 
were divided into two groups using this threshold and progression-free 
survival was compared. 
Results: Among the 30 lesions, 16 recurrences were observed within 
one year after irradiation, while 9 lesions were well controlled for 
more than one year. Five lesions without recurrence were excluded 
because the follow-up period not reached one year. Met-uptake/BED 
was significantly correlated with the control of the lesion (p=0.020). 
The optimal threshold of Met-uptake/BED was calculated as 0.029. 
The progression-free survival time with low Met-uptake/BED (20.2m) 
was significantly longer than the others (4.4m, p=0.004). MGMT-
methylation status also showed borderline significance, but the 
independent significance of Met-uptake/BED was ascertained with 
multivariate analysis (p=0.007). Required dose to control lesions could 
be decided upon the Met-PET using the following formula: BED= Met-
uptake/0.029. 
Conclusions: Required BED to control tumor was significantly 
correlated with the Met-uptake, and new treatment plan based upon 
Met-uptake was proposed. 
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Purpose/Objective: To improve results of treatment of ependymomas 
of the brain in children. 
Materials and Methods: In 1999 - 2011the children's department 
treated 129 children with ependymoma of the brain. All patients 
received after subtotal or partial removal of the tumor. 13% of 
patients on admission revealed metastases in the spinal cord. All 
patients received local or craniospinal radiotherapy with 
chemotherapy by vincristine. 84 (65%) children of radiation therapy 
was initiated within 4 to 7 weeks after surgical resection, and 45 (35%) 
- by 7 weeks after surgery. Daily single dose of 1.8-2Gr/d, total focal 
dose tothe primary tumor area is 55Gr, with craniospinal irradiation 
35Gr the entire volume of CSR. 
Results: At follow-up in 53% of patients had local recurrence and 11% 
had metastases in the brain and spinal cord. There were significant 
differences in overall survival in patients who received radiation 
therapy in terms of 4 to7 weeks and 7 weeks later after surgery. The 
probability of death was in the 1.721 (HR) times lower than in group 1 
(P = 0.028, 95% Cl: 1.061-2.792), than in the second. Analysis of cases 
of recurrence showed that the main risk factor for recurrence was the 
volume of a surgical intervention: in the absence of post-operative 
MRI residual tumor recurrence rate was 17% and 83% of its stock. 
Conclusions: Patients appropriate radiation therapy no later than 4-7 
weeks after surgery. Accumulation of contrast material in the area of 
operation is undoubtedly a poor prognostic factor. The high frequency 
of local recurrence of the tumor demonstrates the need for 
modification techniques local irradiation in the presence of 
radiographic evidence of residual tumor. 
   
EP-1008   
Whole brain virtual simulation: a time-efficient, parotid-sparing 
technique without inter-observer variability 
M.E. O'Cathail1, P.J. Kelly1 
1Cork University Hospital, Radiotherapy, Cork, Ireland Republic of  
 
Purpose/Objective: Whole brain radiotherapy (WBRT) is frequently 
employed in the palliation of brain metastases. Despite the 
introduction of CT-based simulation WBRT planning remains subject to 
both intra- and inter-observer variability. There is increasing 
recognition of the parotid glands as non-target organs-at-risk (OARs) in 
delivering WBRT. Quality of life is of prime importance in the 
palliative setting. Salivary gland dysfunction has the potential to 
adversely impact on quality of life. The purpose of this planning study 
was to develop a time efficient,user-friendly technique to minimise 
parotid dose without compromising target volume coverage in WBRT. 
Materials and Methods: Thirteen patients underwent CT-based 
simulation with orfit immobilization. Using the Varian Eclipse (v8.0) 
TPS, the clinical target volume (CTV) was delineated by auto-
segmentation of the brain. The planning target volume (PTV) was 
defined by adding a 5mm margin. Both parotid glands were contoured 
as OARs. Opposed lateral 6MV beams without collimator rotation were 
used and MLCs were automatically conformed to the PTV with an 
empiric 8mm margin. Dose calculation was performed for each patient 
using this virtual technique and also using a conventional simulation 
technique with collimator rotation. In this way each patient acted as 
his/her own control. We then compared parotid dose-volume 
statistics, target coverage and homogeneity. 
Results: Using the virtual simulation technique, the mean dose for the 
combined parotid glands was reduced to 6.4Gy, compared with 10.9Gy 
using the conventional technique (p=0.026). The combined parotid 
V10, V25 and V30 were significantly reduced using the virtual 
simulation technique. 
Virtual Simulation 
N=13 
Conventional 
Simulation N=13 P Value 
Parotid Dose-Volume Statistics 
V 10 (%) 23.1 40.9 p=0.019
V 25 (%) 5.7 16.1 p=0.03 
V 30 (%) 0.6 5.5 p=0.002
D Min (Gy) 0.7 1 p=0.006
D Max (Gy) 30.8 31.4 p=0.016
Mean Parotid
Doses 
Right (Gy) [IQR] 7.3 [5.3-10.2] 11.2 [8.7-15.2] p=0.022
Left (Gy) [IQR] 6.2 [4.3-10.8] 10.6 [9.2-13.2] p=0.042
Combined 
(Gy)[IQR] 6.4 [4.9-11] 10.9 [9.5-14.5] p=0.026
PTV Coverage 
VPTV 95 (%) 99.6 99.9 p=0.02 
VPTV 107 (%) 5.3 7.7 p=0.058
V 107 (cc) 97.1 141.1 p=0.09 
 
There was no compromise in PTV coverage with the V95 over 99% 
using both techniques. Notably the virtual simulation technique also 
improved homogeneity as the VPTV107% was reduced (5.3% vs. 7.7%, 
p=0.058), although this finding was of borderline significance. 
Conclusions: This study suggests that significant reductions in 
radiation dose to the parotids and improved PTV homogeneity can be 
achieved with this virtual simulation technique. This technique is 
time-efficient, eliminates inter-observer variability and may reduce 
the risk of salivary gland dysfunction in palliative patients. 
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Purpose/Objective: To clarify the clinical significance of conventional 
and stereotactic radiotherapy for WHO grade II-III meningiomas. 
Materials and Methods: Clinical results of conventional and 
stereotactic radiotherapy for WHO grade II/III meningiomas treated 
between 1999 and 2011 were retrospectively reviewed. The patients' 
group included 28 patients with 37 treatment sessions (3 sessions for 2 
patients, 2 sessions for 5 patients, and other 21 patients were treated 
once). The median age of the patients at treatment were 70 years 
(range: 13-83 years). The patients experienced a median of 2 times 
(range: 1-5 times) of surgeries before radiotherapy. Pathological 
diagnoses at the most recent surgery were atypical meningiomas 
(WHO grade II)in 30 treatment sessions and anaplastic meningiomas 
(WHO grade III) in 7 sessions. Other subtypes of WHO grade II-III 
meningiomas were not treated in our institution within the period. 
Treatment sessions included 27 stereotactic radiosurgeries (SRSs) by 
